SPOTLIGHT: Intercell to acquire Iomai


Austria's Intercell is buying Iomai for $189 million in cash and stock. The deal will add Iomai's patch to prevent traveler's diarrhea and an adjuvant for bird flu vaccine that has produced impressive data. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.